This microbial imbalance can impair immune function, affect brain health, and elevate systemic inflammation, all of which contribute to the development of various health issues (Ullah et al., 2023)
3 RGN-259 Phase 3 Trial in Neurotrophic Keratopathy Sosne et al., International Journal of Molecular Sciences (2022) This Phase 3 randomized, placebo-controlled, double-masked clinical trial evaluated topical 0.1% RGN-259 (full-length recombinant T4 ophthalmic solution) in patients with neurotrophic keratopathy
Click here to access the 3-Tier Pharmacy formulary booklet
FDA Category 2 Peptide List Update, April 2026
interakcje zwizku z ukadem naczyniowym oraz modulacj odpowiedzi zapalnej
Strength Training, GLP-1, and Turmeric: A Practical Wellness Guide Optimizing your health is no longer about a single solution